Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Healthcare companies are pushing the status quo by ...

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...

Assess today's live Priority Income Fund Inc Pref Series D (PRIF_pd) share price, performance and insights using our live NYSE: PRIF_pd stock exchange data. Analyse the historical data and Priority ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

For instance, Biogen’s Nusinersen (Spinraza), a first-of-its-kind ... Additionally, the FDA’s approval of AMONDYS 45 in February 2021, developed by Sarepta Therapeutics for Duchenne muscular dystrophy ...